Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012058276 - METHODS AND MATERIALS FOR REDUCING MUTIPLE RISK FACTORS ASSOCIATED WITH THE METABOLIC SYNDROM

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A dietary supplement composition comprising:

Nelumbo nucifera or an extract thereof.

2. The composition of claim 1 comprising an extract of Nelumbo nucifera with 1 percent or more flavonoids.

3. The composition of claims 1 or 2 further comprising:

an extract of cinnamon.

4. The composition of any of claims 1 or 2 further comprising creatine, a precursor of creatine, or a derivative of creatine.

5. The composition of claims 1 or 2 wherein said dietary supplement comprises from 1 milligram to 1000 milligram of Nelumbo nucifera, Nelumbo nucifera extract, or derivative of a Nelumbo nucifera extract per gram of dietary supplement.

6. A process for altering two or more risk factors associated with metabolic syndrome in a subject, comprising the step of:

administering to said subject a therapeutically effective amount of a Nelumbo nucifera extract.

7. The process of claim 6 wherein said therapeutically effective amount is from 10 milligrams to 1,000 milligrams of said Nelumbo nucifera extract.

8. The process of claims 6 or 7 wherein said extract is administered as a formulation prepared as a liquid preparation, solid preparation, capsule preparation, or a powder preparation.

9. The process of claims 6 or 7, wherein at least one of said the risk factors, as defined by NCEP-ATP-III, is abnormal systolic blood pressure, abnormal fasting blood glucose, abnormal body mass index, abnormal high-density lipoprotein, abnormal low-density lipoprotein, or abnormal blood triglyceride.

10. The process of claims 6 or 7, wherein the therapeutically effective amount of said extract is administered orally, intravenously, by intramuscular injection, by intraperitoneal injection, or transdermally.

11. The process of claims 6 or 7, wherein the therapeutically effective amount of a nelumbo extract is administered orally in the form of tablets, suppositories, pills, capsules, powders, liquids, or suspensions.

12. The method of claims 6 or 7, wherein the therapeutically effective amount of a nelumbo extract supplement comprises a predetermined amount of flavanoids.

13. The process of claims 6 or 7 wherein said extract is the extract of claims 1, 2, or

30.

14. The process of claims 6 or 7 wherein said subject is pre-diabetic or not diabetic.

15. A process of altering one or more risk factors of metabolic syndrome substantially as described herein.

16. Use of the composition of claims 1 or 2 for preparing a preparation for altering two or more risk factors of metabolic syndrome wherein said composition comprises a pharmaceutically acceptable carrier.

17. Use of the composition of claim 3 for preparing a preparation for altering two or more risk factors of metabolic syndrome wherein said composition comprises a pharmaceutically acceptable carrier.

18. A process of altering the mRNA levels encoding IR, IRS-1, IRS-2, Aktl, or PDKrl in a cell of a subject comprising:

administering to said subject an extract of Nelumbo nucifera.

19. A process of altering the mRNA levels encoding SREBP1, MTP or PTEN in a cell of a subject comprising:

administering to said subject an extract of Nelumbo nucifera.

20. A process of altering the mRNA levels encoding IL-lcc, IL-Ιβ, IL-6 or TNF-a in a cell of a subject comprising:

administering to said subject an extract of Nelumbo nucifera.

21. The process of any of claims 18-20 wherein said extract is administered in a concentration of 100 to 200 milligrams per kilogram of body weight of said subject.

22. The process of any of claims 18-20 wherein said extract is the extract of claims 1 or 2.

23. The process of any of claims 18-20 wherein said extract further comprises an extract of cinnamon.

24. The process of any of claims 18-20 wherein said extract is present at 100 micrograms per milliliter.

25. The process of any of claims 18-20 wherein said cell is an enterocyte.

26. The extract of claims 1 or 2 further comprising one or more of a vitamin, a glucose lowering agent, corosolic acid, momordica, cecropia, a blood pressure lowering agent, epigallocatechin gallate, and lipid lowering agent, or a lipid lowering agent.

27. The process of claims 6 or 7 wherein said extract is a component of a dietery supplement, said dietary supplement further comprising one or more of a vitamin, a glucose lowering agent, corosolic acid, momordica, cecropia, a blood pressure lowering agent, epigallocatechin gallate, and lipid lowering agent, or a lipid lowering agent.

28. The composition of claims 1 or 2 further comprising epigallocatechin gallate.

29. The composition of claims 1 or 2 further comprising creating monohydrate.

30. The composition of claim 2 further comprising one or more phytosterols.

31. The composition of claim 30 wherein said phytosterols comprise one or more of policosanol, β-sitosterol, campesterol, stigmasterol, or sitostanol.